KYOWA-KIRIN
On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER)”, a prospective observational study evaluating the real-world impact of mogamulizumab on disease symptoms and health-related quality of life (HRQoL) in patients with these subtypes of cutaneous T-cell lymphoma (CTCL).
CTCL is a rare form of non-Hodgkin lymphoma that most prominently affects the skin, presenting as patches, plaques, tumours, or reddening of the entire skin, and may be associated with severe itching. In a proportion of cases, the disease may spread to the lymph nodes, blood, and/or other organs.
In the current interim analysis, symptom scores (mean) were reported for 20 adult patients with relapsed or refractory disease (8 MF; 12 SS) over their first 16 weeks of mogamulizumab treatment. Prior to treatment initiation, patients reported their symptom burden using a 1 – 10 numeric scale. At baseline, skin itch scored highest (6.6) followed by skin redness (6.2), flaking skin (5.9) and skin pain (4.0). Additionally, over half of patients reported having sleep problems either “frequently” or “every night” while 47% reported difficulties regulating body temperature “frequently” or “always”.
Improvement in all symptoms was reported within 4 weeks of treatment initiation and by week 16, symptom severity had decreased considerably with the greatest improvement seen in skin redness (-2.9) closely followed by skin itch (-2.7), flaking skin (-2.5) and skin pain (-2.2). Of note, the proportion of patients reporting sleep problems or difficulties regulating body temperature either “frequently” or “always” decreased to less than 20%.
“We know that CTCL patients not only suffer from the stress of a cancer diagnosis, but that these stresses are compounded by painful, red, scaly, and itchy lesions, tumours, and varying levels of discomfort,” says study principal investigator, Prof. Julia Scarisbrick of the University of Birmingham. “The PROSPER study is helping us understand these burdens better and the impact mogamulizumab may have on patients’ symptoms and quality of life.”
To view the full press release, click here.
KKI/INT/MOG/1081
Date of Preparation: April 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240415169712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
L&T Technology Services Transforms Respiratory Diagnostics with NVIDIA AI-Powered Digital Twin Technology1.12.2025 08:30:00 CET | Press release
Collaboration brings together LTTS’ expertise in MedTech and NVIDIA AI infrastructure to deliver precision diagnostics and enhance patient care L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & R&D Consulting Services, today announced the development of a next-gen AI-powered digital twin platform for respiratory diagnostics and lung navigation. Combining LTTS’ expertise in platform engineering, AI-driven diagnostics, connected health systems and advanced imaging and visualization with cutting-edge NVIDIA AI infrastructure, LTTS aims to deliver scalable, low-latency solutions that enhance diagnostic precision and improve accessibility for healthcare providers worldwide. To be unveiled at the Radiological Society of North America (RSNA) 2025, the LTTS solution integrates with CT imaging and leverages deep learning models to create a 3D digital twin of lung anatomy, providing visualization of airways, blood vessels, lung lobes and lesions. Powered by NVIDI
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business1.12.2025 08:00:00 CET | Press release
The deal strengthens Regnology’s leadership in compliance technology, expands capabilities in risk and finance, and reinforces its commitment to innovation and client continuity. Regnology, a global leader in regulatory reporting and supervisory technology, today announces the successful closing of its acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) business. This milestone reinforces Regnology’s position as the trusted partner for financial institutions and regulators worldwide, delivering smarter, faster compliance solutions at scale. Regnology is committed to ensuring business continuity for all FRR clients. With a proven track record in seamless migrations and a unified data model on a scalable SaaS platform, institutions can maintain compliance securely and efficiently throughout the integration process. The acquisition underscores Regnology’s vision to combine regulatory expertise with innovation. The recently launched RRH Ascend platform exemplifies th
Ant International Upgrades Antom Copilot to Advance Domain-Specific Agentic AI to Solve Global Payment Complexity1.12.2025 07:21:00 CET | Press release
Antom, a leading merchant payment and digitisation services provider under Ant International, today announced major upgrades to Antom Copilot, its industry-first AI agent designed for merchant payment and operations management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251130027598/en/ Antom Copilot supports a wide range of merchant payment operations and responds to early signs of issues with tailored recommendations. Integrated into the Antom Merchant Portal, Antom Copilot now provides enhanced automation and tailored assistance based on learnings from real-world cases, to help merchants handle payment complexity more efficiently. Main features include: Agentic support for entire payment lifecycle, from onboarding and integration, to dispute handling, risk control and payment success rate operation; Domain-trained intelligence functions like a virtual team of payment experts to manage traditionally resource-intensive
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 07:00:00 CET | Press release
OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial) become available across Europe as of December 2025 and January 2026, respectivelyMarks Samsung Bioepis’ 10th and 11th biosimilars launched in Europe and second and third product to be commercialized directly by Samsung BioepisLaunch reinforces Samsung Bioepis’ biosimilar leadership in Europe as it expands its portfolio into endocrinology and builds on its growing direct sales efforts Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a pa
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 22:31:00 CET | Press release
The world’s first assessment to assess AI models’ alignment with Emirati identity and values The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom